Signals
14Hyperemesis gravidarum therapy options widen past doxylamine-pyridoxine
Doxylamine-pyridoxine and ondansetron maturity, structured outpatient infusion pathways, and emerging GDF15-targeted programs are reshaping hyperemesis gravidarum management.
Thyroid disease in pregnancy management formalises around structured monitoring
Pregnancy-specific TSH targets, structured pre-conception thyroid management, and integrated maternal-fetal medicine and endocrinology pathways are reshaping thyroid disease in pregnancy.
Genitourinary syndrome of menopause therapy widens past systemic hormone therapy
Vaginal estrogen formulation maturity, ospemifene and prasterone uptake, and emerging non-hormonal mechanism programs are restructuring genitourinary syndrome of menopause management.
Pelvic floor disorder therapy options widen past Kegel-and-surgery defaults
Pelvic floor physiotherapy formalisation, vibegron and emerging beta-3 agonist programs in overactive bladder, and integrated multidisciplinary care models are reshaping pelvic floor disorders.
Vasomotor symptom therapy expands past fezolinetant
Elinzanetant approval, follow-on NK3 receptor antagonist programs, and combination NK1-NK3 approaches are restructuring vasomotor symptom management.
Breast cancer survivorship care widens past tamoxifen and aromatase inhibitor side-effect management
Vasomotor symptom therapy in breast cancer survivors, bone-health management with aromatase inhibitors, and structured survivorship programs are reshaping breast cancer survivorship care.
Postmenopausal osteoporosis therapy reshapes around anabolic-first sequencing
Romosozumab maturity, ongoing teriparatide and abaloparatide use, and follow-on anabolic programs are restructuring postmenopausal osteoporosis sequencing.
Pre-eclampsia prediction and prevention infrastructure matures
sFlt-1 to PlGF ratio testing in suspected pre-eclampsia and aspirin-prophylaxis pathway adoption are reshaping pre-eclampsia care.
Fertility therapy moves from procedural to pharmacological
Pharmacological adjuncts and oocyte-quality interventions are expanding the fertility-therapy toolset beyond the IVF procedural footprint.
Uterine fibroid GnRH antagonist combination therapy is displacing surgical-only management
GnRH antagonist combination therapy (with add-back hormone) for uterine fibroids has expanded medical management options for a condition that was historically managed primarily through surgery. The commercial implications across surgical referral patterns, fertility-preservation framing, and adjacent gynaecological pipeline are material.
Postpartum depression novel mechanism uptake reveals the maternal-mental-health access gap
The approval of zuranolone for postpartum depression introduced a rapid-acting oral mechanism into a previously underserved indication. Real-world uptake patterns reveal the structural access gap in maternal mental health, with material implications for the commercial trajectory of adjacent maternal mental health pipeline.
PARP inhibitors in ovarian cancer maintenance are facing access pressure
Real-world ovarian cancer PARP maintenance use across major markets shows access pressure: prior-authorisation criteria tightening, payer-side post-marketing evidence demands, and ongoing reassessment of the eligible-population framing.
Menopause prescribing patterns are normalising after a decade of post-WHI under-treatment
Hormone therapy and non-hormonal vasomotor symptom prescribing patterns are normalising across major markets, reflecting accumulating real-world safety evidence and the emergence of non-hormonal mechanisms. The commercial category that the post-WHI period suppressed is being rebuilt.
Non-hormonal vasomotor symptom options are now in routine use
Fezolinetant uptake has been faster than analyst projections, and the field is now in the post-launch phase where prescribing patterns, payer coverage, and longer real-world safety data shape adoption.
Snapshots
6Nausea and vomiting in pregnancy therapy reference (2026)
Reference snapshot of nausea and vomiting in pregnancy therapy from mild morning sickness through hyperemesis gravidarum.
Overactive bladder therapy reference (2026)
Reference snapshot of overactive bladder therapy across behavioural, pharmacological, and procedural tiers.
Vasomotor symptom therapy reference (2026)
Reference snapshot of vasomotor symptom therapy across hormone, non-hormonal pharmacotherapy, and emerging mechanism-targeted tiers.
Postmenopausal osteoporosis therapy reference (2026)
Reference snapshot of postmenopausal osteoporosis therapy across anti-resorptive and anabolic tiers.
Maternal mental health pipeline, 2026 mid-year reference
Reference layout of the maternal mental health pipeline as of mid-2026: approved mechanisms for postpartum depression, late-stage assets for perinatal mood disorders and adjacent indications, and the live commercial questions including screening pathway and access frame.
Endometriosis pipeline, 2026 mid-year reference
Reference layout of the endometriosis pipeline as of mid-2026: approved mechanisms, late-stage assets, the GnRH antagonist class, the non-hormonal pipeline, and the live commercial questions including diagnosis-pathway access and the surgical-medical interplay.
Explained
5What is hyperemesis gravidarum?
Plain-language primer on hyperemesis gravidarum, why it is more than morning sickness, and what comprehensive care can offer.
What is overactive bladder?
Plain-language primer on overactive bladder, why it is common, and what the modern therapy options can offer.
What are vasomotor symptoms?
Plain-language primer on hot flashes and night sweats, why they happen, and what the modern therapy options can offer.
Postmenopausal osteoporosis explained
Plain-language primer on postmenopausal osteoporosis, why bone changes after menopause, and how modern therapy works.
How contraception innovation is being reshaped by the long-acting reversible class
Contraceptive innovation has shifted from oral and short-acting options toward long-acting reversible contraception (LARC) including hormonal IUDs, copper IUDs, and contraceptive implants. The commercial logic, the access frame, and the implications for the broader reproductive health pipeline are worth understanding.